Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Shanmiao Gou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1988-0901; OpenAlex author ID A5027495299. Sources: OpenAlex.

Their work

Papers
29 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 4 papers · 2026: 3 papers

Papers 29

  1. Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2026.102128↗
  2. HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1α transcriptional activation in pancreatic cancer. Co-author DOI 10.1016/j.molcel.2026.06.022↗
  3. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0923↗
  4. Targeted intervention in nerve-cancer crosstalk enhances pancreatic cancer chemotherapy. Co-author DOI 10.1038/s41565-024-01803-1↗
  5. [Emphasizing Principles of Surgical Oncology in Minimally Invasive Surgery for Pancreatic Cancer]. Co-author DOI 10.12182/20250760103↗
  6. Retraction: MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Co-author DOI 10.18632/oncotarget.28806↗
  7. BAP1 Represses Sequential Activation of IRAKs and NF-κB Signaling in Pancreatic Cancer. Co-author DOI 10.7150/ijbs.104977↗
  8. miR-222-3p-containing macrophage-derived extracellular vesicles confer gemcitabine resistance via TSC1-mediated mTOR/AKT/PI3K pathway in pancreatic cancer. Co-author DOI 10.1007/s10565-022-09736-y↗
  9. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2. Co-author DOI 10.1016/j.biopha.2023.115359↗
  10. Tumor Cell Derived Exosomal GOT1 Suppresses Tumor Cell Ferroptosis to Accelerate Pancreatic Cancer Progression by Activating Nrf2/HO-1 Axis via Upregulating CC… Co-author DOI 10.3390/cells11233893↗
  11. COL11A1 is the Key Target Gene of MIST1 on Tumor Progression of Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-793040/v1↗
  12. [Indications and efficacy of neoadjuvant therapy for pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112137-20201121-03157↗
  13. Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. Last author DOI 10.1016/j.omto.2020.03.006↗
  14. COL11A1 acted as a downstream of Mist1 to promote the EMT in pancreatic cancer Last author DOI 10.21203/rs.3.rs-108113/v1↗
  15. Overexpression of MIST1 reverses the epithelial-mesenchymal transition and reduces the tumorigenicity of pancreatic cancer cells via the Snail/E-cadherin pathw… Co-author DOI 10.1016/j.canlet.2018.05.043↗
  16. Impact of age on survival of patients with pancreatic cancer after surgery: Analysis of SEER data. Co-author DOI 10.1016/j.pan.2017.11.008↗
  17. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Co-author DOI 10.1038/s41598-017-06207-x↗
  18. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway. Co-author DOI 10.1186/s12943-017-0627-6↗
  19. Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. Co-author DOI 10.1007/s11596-016-1567-x↗
  20. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Last author DOI 10.18632/oncotarget.7482↗
  21. Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling. Last author DOI 10.1038/srep14404↗
  22. MiR-744 increases tumorigenicity of pancreatic cancer by activating Wnt/β-catenin pathway. Co-author DOI 10.18632/oncotarget.5317↗
  23. Oncogenicity of LHX2 in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s11033-014-3716-2↗
  24. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. Co-author DOI 10.1186/1471-2407-14-370↗
  25. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. Co-author DOI 10.1371/journal.pone.0114581↗
  26. Low concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer action. Co-author DOI 10.1371/journal.pone.0063969↗
  27. ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2011.10.033↗
  28. [Expression of hypoxia inducible factor-1α and insulin in pancreatic cancer and their correlation]. Co-author DOI 10.3760/cma.j.issn.0253-3766.2012.05.006↗
  29. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Co-author DOI 10.1159/000334103↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 12 shared papers, 2011–2026 · strength 1.93
  2. Chunyou Wang · 14 shared papers, 2011–2025 · strength 1.04
  3. Yingke Zhou · 3 shared papers, 2025–2026 · strength 0.72
  4. Gengdu Qin · 3 shared papers, 2025–2026 · strength 0.72
  5. Tao Yin · 6 shared papers, 2011–2026 · strength 0.71
  6. Zhiqiang Liu · 7 shared papers, 2016–2021 · strength 0.70
  7. Taoyu Chen · 3 shared papers, 2022–2026 · strength 0.66
  8. Tao Peng · 3 shared papers, 2022–2023 · strength 0.59
  9. Haixin Yu · 2 shared papers, 2025–2026 · strength 0.47
  10. Xiaogang Li · 4 shared papers, 2017–2020 · strength 0.42
  11. Haijiao Yan · 2 shared papers, 2015–2025 · strength 0.32
  12. Dianyun Ren · 2 shared papers, 2020–2021 · strength 0.28
  13. Hengwei Wu · 1 shared paper, 2021 · strength 0.28
  14. Wei Zhou · 1 shared paper, 2025 · strength 0.27
  15. Tao Liu · 1 shared paper, 2025 · strength 0.27
  16. Shuhan Zhao · 1 shared paper, 2026 · strength 0.26
  17. Jun Xue · 1 shared paper, 2026 · strength 0.26
  18. Yizhou Liu · 1 shared paper, 2026 · strength 0.26
  19. Hongkun Cai · 1 shared paper, 2026 · strength 0.26
  20. Yongfeng Li · 3 shared papers, 2016–2020 · strength 0.25
  21. Yuhan Zhao · 1 shared paper, 2025 · strength 0.24
  22. Jing Cui · 1 shared paper, 2023 · strength 0.22
  23. Yao Guo · 1 shared paper, 2023 · strength 0.22
  24. Xin Li · 1 shared paper, 2025 · strength 0.21
  25. Lu Gan · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.